harmacare
Research Paper
A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds
Hilary Short, Tania Stafinski and Devidas Menon
Discussion and Debate
Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly’s Canadian 40over40 Erectile Dysfunction Campaign
Jean-Christophe Bélisle Pipon and Bryn Williams-Jones
Data Matters
The Drivers of Overspending on Prescription Drugs in Quebec
Kate Smolina and Steve Morgan
Rapport De Recherche
Trois types de stratégies des fabricants pour la fidélisation aux médicaments de marque
Marie-Claude Prémont and Marc-André Gagnon
Facts-at-a-Glance
Prescribed Drug Spending in Canada, 2012
Discussion and Debate
Health Canada and the Pharmaceutical Industry: A Preliminary Analysis of the Historical Relationship
Joel Lexchin
Discussion and Debate
Health Canada and the Pharmaceutical Industry: A Preliminary Analysis of the Historical Relationship
Joel Lexchin
Value for Money
Piloting an Outpatient Policy for Funding Drugs and Their Administration in Rheumatology
Bernadette Chevalier, Christy Simpson, Heather Hemming, Anne Hiltz, Randi Monroe and Victoria Sulliv...
Data Matters
Cost-Control Mechanisms in Canadian Private Drug Plans
Jillian Kratzer, Kimberlyn McGrail, Erin Strumpf and Michael R. Law